Trump Order Spurs FDA to Speed Reviews of Psychedelic Therapies
Summary
The Food and Drug Administration (FDA) has decided to speed up the review process for three psychedelic drug treatments aimed at serious mental health issues. This change follows an executive order from President Donald Trump that pushes federal agencies to quicken research and ease rules on psychedelic drugs, which are still illegal under federal law.Key Facts
- The FDA will fast-track reviews for two psilocybin treatments for depression that does not respond to other therapies.
- A treatment using methylone for Post-Traumatic Stress Disorder (PTSD) will also get priority review.
- Priority review vouchers allow the FDA to evaluate these treatments in weeks instead of months.
- The vouchers do not guarantee the drugs will be approved.
- The Trump administration is increasing support for research on psychedelic medicines.
- Veterans’ groups and political supporters have asked for faster access to these experimental treatments.
- Psychedelic drugs remain illegal under federal law despite the push to study them more quickly.
- This is one of the most assertive actions so far in the Trump administration’s effort to promote psychedelic therapy research.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.